The purpose of this study is to estimate the prevalence of genetic variants associated with liver disease in participants who are known, or are likely to have NAFLD.

Inclusion Criteria:

• No clinically significant abnormality based on medical history, physical exam, and 12-lead electrocardiogram (ECG) collected during Visit 1
• Women must be of non-childbearing potential, defined as either: a.) Postmenopausal or b.) Permanently sterile
• Must be willing to provide a deoxyribonucleic acid (DNA) sample for assessment of genetic variants associated with NAFLD
• Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study

Exclusion Criteria:

• History or presence of drug abuse within the 2 years prior to Visit 1
• Excessive use of alcohol within 2 years prior to the study
• Body mass index greater than (>) 40 kilogram per meter square (kg/m^2)
• Evidence of other active (acute or chronic) liver disease other than NAFLD/ Nonalcoholic steatohepatitis (NASH)
• History of bariatric surgery or planning to undergo bariatric surgery within the next year
• Inability to undergo magnetic resonance imaging (MRI)

Participants, who are known to have, or are likely to have, NAFLD.

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu